Please check your internet connection and try again.
# Norad (norepinephrine)
## Overview
Norepinephrine is a potent catecholamine with primary alpha-1 adrenergic activity (vasoconstriction) and moderate beta-1 adrenergic activity (inotropy). It is the first-line vasopressor for septic shock.
## Primary Indications
* Acute hypotensive states (e.g., septic shock, cardiogenic shock).
* Hemodynamic support during cardiac arrest (rarely first-line).
## Adult Dosing
* **Initial:** 0.05–0.1 mcg/kg/min via continuous IV infusion.
* **Titration:** Titrate by 0.05–0.2 mcg/kg/min every 2–5 minutes to achieve target Mean Arterial Pressure (MAP), typically ≥65 mmHg.
* **Maintenance:** 0.01–3 mcg/kg/min. High doses (>1 mcg/kg/min) significantly increase risk of tissue ischemia.
* *Note:* Exact titration protocols vary by institutional policy; always follow local ICU guidelines.
## Pediatric Dosing
* **Initial:** 0.05–0.1 mcg/kg/min.
* **Titration:** Titrate as needed to maintain age-appropriate perfusion.
* **Maximum:** Doses up to 1–2 mcg/kg/min have been reported in severe refractory shock, but pediatric data is limited compared to adult populations.
## Dose Adjustments
* **Hepatic/Renal Impairment:** No specific adjustment required; however, patients with organ failure may demonstrate increased sensitivity.
* **Tapering:** Must be tapered gradually to prevent rebound hypotension.
## Contraindications
* Hypersensitivity to norepinephrine or bisulfites.
* Hypotension due to uncorrected blood volume deficit (except as an emergency measure to maintain coronary/cerebral perfusion during volume resuscitation).
## Adverse Effects
* **Cardiovascular:** Hypertension, bradycardia (reflex), arrhythmias, myocardial ischemia.
* **Local:** Extravasation can lead to severe tissue necrosis and sloughing (treat with phentolamine infiltration).
* **Systemic:** Peripheral/visceral ischemia, metabolic acidosis (due to decreased tissue perfusion).
## Key Drug Interactions
* **MAO Inhibitors/TCAs:** May cause severe, prolonged hypertension.
* **Beta-Blockers:** May block beta-activity, leading to unopposed alpha-mediated vasoconstriction and severe hypertension/bradycardia.
* **Halogenated Anesthetics:** Increased risk of ventricular arrhythmias.
## Monitoring
* **Hemodynamics:** Continuous invasive blood pressure monitoring (A-line) is highly recommended.
* **Perfusion:** Monitor urine output, serum lactate, and peripheral extremity warmth/color.
* **Site:** Inspect IV site frequently for signs of extravasation.
* **ECG:** Continuous monitoring for arrhythmias.
## Clinical Pearls
* **Administration:** Must be administered via a **central venous catheter** whenever possible to avoid extravasation injury. If peripheral administration is necessary, use a large vein (proximal) and dilute appropriately; use only for short-term emergency stabilization.
* **Compatibility:** Administer through a dedicated line or verify Y-site compatibility; norepinephrine is inactivated by alkaline solutions.
* **Volume Status:** Norepinephrine is not a substitute for fluid resuscitation; ensure adequate volume status is achieved or concurrent fluid therapy is underway.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution. Always verify specific dosing, safety data, and compatibility with your local formulary, current prescribing information, and institutional protocols before administration.
